Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate

被引：0
|
作者：
Januszewski, Andrzej S.
Young, Hayden K.
Li, Liping
Oconnell, Rachel L.
Lyons, Timothy
Kelly, Clare B.
Sullivan, David
Scott, Russell
Keech, Anthony C.
Jenkins, Alicia
机构：
来源：
DIABETES | 2019年 / 68卷
基金：
英国医学研究理事会;
关键词：
D O I：
10.2337/db19-139-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
139-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [31] FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY
    Rajamani, K.
    Donoghoe, M.
    Li, L.
    Ting, R. -D.
    Colman, P.
    Scott, R.
    Laakso, M.
    Keech, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 219 - 220
  • [32] Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease
    Costa-Mallen, Paola
    Zabetian, Cyrus P.
    Hu, Shu-Ching
    Agarwal, Pinky
    Yearout, Dora
    Checkoway, Harvey
    JOURNAL OF NEURAL TRANSMISSION, 2016, 123 (11) : 1319 - 1330
  • [33] Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Michael C. d’Emden
    Alicia J. Jenkins
    Liping Li
    Diana Zannino
    Kristy P. Mann
    James D. Best
    Bronwyn G. A. Stuckey
    Kris Park
    Juha Saltevo
    Anthony C. Keech
    Diabetologia, 2014, 57 : 2296 - 2303
  • [34] Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    d'Emden, Michael C.
    Jenkins, Alicia J.
    Li, Liping
    Zannino, Diana
    Mann, Kristy P.
    Best, James D.
    Stuckey, Bronwyn G. A.
    Park, Kris
    Saltevo, Juha
    Keech, Anthony C.
    DIABETOLOGIA, 2014, 57 (11) : 2296 - 2303
  • [35] Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease
    Paola Costa-Mallen
    Cyrus P. Zabetian
    Shu-Ching Hu
    Pinky Agarwal
    Dora Yearout
    Harvey Checkoway
    Journal of Neural Transmission, 2016, 123 : 1319 - 1330
  • [36] PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
    Feng, Xiaomeng
    Gao, Xia
    Jia, Yumei
    Zhang, Heng
    Pan, Qingrong
    Yao, Zhi
    Yang, Ning
    Liu, Jia
    Xu, Yuan
    Wang, Guang
    Yang, Xinchun
    PPAR RESEARCH, 2015, 2015
  • [37] Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy
    Harmer, Jason A.
    Keech, Anthony C.
    Veillard, Anne-Sophie
    Skilton, Michael R.
    Marwick, Thomas H.
    Watts, Gerald F.
    Meredith, Ian T.
    Celermajer, David S.
    ATHEROSCLEROSIS, 2015, 242 (01) : 295 - 302
  • [38] Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
    Sun, Xiaomeng
    Liu, Jia
    Wang, Guang
    LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)
  • [39] Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
    Xiaomeng Sun
    Jia Liu
    Guang Wang
    Lipids in Health and Disease, 19
  • [40] Effects of fenofibrate on plasma level of ubiquinol-10 in type 2 Diabetes Mellitus with hyperlipidemia
    Asano, A
    Kobayashi, J
    Murase, Y
    Yamaaki, N
    Yagi, K
    Mabuchi, H
    DIABETES, 2005, 54 : A236 - A236
12345